ArticleIndian journal of clinical biochemistry : IJCB2025
Exon Sequence Analysis of the
Article in Indian journal of clinical biochemistry : IJCB, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy (RT) which is a treatment regime for cancer patients may cause genetic instability and side effects. Etiological associations exist amongst autophagy-related gene (ATG) mutation and cancer. RT increases the rate of autophagy previously proven in vitro. The aforementioned background diverted us to conduct exon mutation analysis for ATG5, ATG12, and ATG9B genes of colorectal cancer patients who were receiving neoadjuvant RT. Peripheral blood DNA from different time points (before/middle/after RT) of the same patients was isolated and most tandem repeat-containing exons of ATG5, ATG12, and ATG9B were polymerase chain reaction-amplified and examined for mutations by Sanger sequencing. CA19-9/CEA (Tumor marker of colorectal cancer/Carcinoembryonic Antigen) serum levels were retrieved from the clinic. No exon variations detected for ATG5 and ATG12 genes. However, 4 patients (17.4%) showed frameshift mutation for ATG9B gene. Exon variation analysis of 2 (8.7%) patients resulted in GGG deletion at 8G mononucleotide tandem repeat region of ATG9B. Assigning patients as before RT and after RT, CA19-9 levels in ATG9B (Mutation) patients were higher compared to ATG9B (Wild Type) patients. ATG9B is highly likely to mutate during RT and ATG9B mutation correlates to higher CEA and CA19-9 levels and patients show poor prognosis. Supplementary Information: The online version contains supplementary material available at 10.1007/s12291-023-01177-6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.